title: Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide.
abstract: A cholesterol-rich microemulsion (LDE) that binds to low-density lipoprotein (LDL) receptors is selectively taken up by malignant cells that overexpress those receptors and may be used as vehicle for antineoplastic agents. This study aimed to develop the association of etoposide with LDE. It was firstly observed that etoposide poorly associates with the microemulsion, therefore the experiments were performed with a lipophilic fatty acid derivative of the drug. The association of etoposide oleate with LDE was almost 100% and was tested for physical and chemical stability, as well as for cellular uptake, toxicity in mice and cytotoxic activity against a neoplastic cell line (NCI-H292). Uptake and cytotoxic activity of LDE-etoposide oleate by NCI-H292 cells was mediated by LDL receptors. The anti-proliferative activity of LDE-etoposide oleate against the neoplastic cells was smaller than that of etoposide oleate (IC50 (drug concentration required to inhibit 50% of the cell growth) = 0.48 and 0.19 mM, respectively). This difference, however, can be ascribed to the activity of the commercially used vehicle and not the drug itself because when this vehicle was added to the cultures with LDE-etoposide oleate, the IC50 decreased. On the other hand, the tolerability of LDE-etoposide oleate to mice was remarkable, such that its lethal dose (LD50) was about five-fold that of the commercial formulation (LD50 = 315 and 58 mg kg(-1), respectively). In conclusion, LDE-etoposide oleate association is stable and the cytostatic activity of the drug is preserved while its toxicity to animals is small. By diminishing the side effects and directing etoposide to neoplastic tissues, LDE may be regarded as an advance in chemotherapy with this drug.
authors.affiliation: Lipid Metabolism Laboratory, the Heart Institute (InCor) of the Medical School Hospital, São Paulo, Brazil.
authors.forename: Claudete J
authors.initials: CJ
authors.lastname: Valduga
authors.forename: Denise C
authors.initials: DC
authors.lastname: Fernandes
authors.forename: Ana C
authors.initials: AC
authors.lastname: Lo Prete
authors.forename: Carolina H M
authors.initials: CH
authors.lastname: Azevedo
authors.forename: Debora G
authors.initials: DG
authors.lastname: Rodrigues
authors.forename: Raul C
authors.initials: RC
authors.lastname: Maranhão
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid; D004655:Emulsions; D005047:Etoposide / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D007928:Lethal Dose 50; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011973:Receptors, LDL / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004655:Emulsions; D011973:Receptors, LDL; D005047:Etoposide